title: Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.
abstract: In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90%. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.
authors.affiliation: Division of Pediatric Hematology, Oncology, Stem Cell Transplantation, Columbia University Medical Center, New York, NY 10032, USA. kk291@columbia.edu
authors.forename: Kara M
authors.initials: KM
authors.lastname: Kelly
authors.forename: David
authors.initials: D
authors.lastname: Hodgson
authors.forename: Burton
authors.initials: B
authors.lastname: Appel
authors.forename: Lu
authors.initials: L
authors.lastname: Chen
authors.forename: Peter D
authors.initials: PD
authors.lastname: Cole
authors.forename: Terzah
authors.initials: T
authors.lastname: Horton
authors.forename: Frank G
authors.initials: FG
authors.lastname: Keller
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D059248:Chemoradiotherapy; D002648:Child; D002986:Clinical Trials as Topic; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D011379:Prognosis; D011878:Radiotherapy; D012106:Research; D012307:Risk Factors